# MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

> **NCT03089645** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 39 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** MEDI5083 monotherapy
- **BIOLOGICAL:** MEID5083 with Durvalumab or Tremelimumab
- **BIOLOGICAL:** Medi5083 with Durvalumab and Docetaxel

## Key facts

- **NCT ID:** NCT03089645
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-21
- **Primary completion:** 2020-06-23
- **Final completion:** 2020-06-23
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03089645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03089645, "MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03089645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*